Efficacy in participants based on baseline intracranial lesions
intracranial target lesions
BRAIN METASTASES
Totally 88 (33.33%) participants had brain metastases at baseline, among whom 40 (15.15%) had intracranial target lesions. As shown in Supplementary Table 